EGFR and cancer: Therefore, to optimize therapeutic response for the management of mCRC, it would be key to identify molecular mechanisms able to induce both primary and acquired resistance to anti-EGFR mAbs, detect pre-existing gene alterations, and monitor the onset of de novo abnormalities restraining cancer sensitivity to anti-EGFR mAbs.